An observational study in Mycosis Fungoides/Sezary Syndrome and Cutaneous T Cell Lymphoma, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Cutaneous T-cell lymphomas (CTCL) are a group of primary cutaneous lymphomas including Mycosis Fungoides (MF) and Sézary syndrome (SS). SS is characterized by erythroderma and high numbers of circulating atypical lymphocytes (Sézary cells. SCs). Blood staging was added to the Tumor Node Metastasis (TNM) classification of MF/SS, reflecting the broad spectrum of CTCLs and the poor prognosis related to blood involvement. Blood classes were defined using blood-smear manual counts. However, this method never reached an international consensus status because of its subjective nature and its poor sensitivity. Several markers have been identified with variable efficiency for MF/SS diagnosis, outcome prediction and blood response to treatment. Such markers are essential for sharing and publishing consistent data about diagnosis, staging, prognosis and response to therapies. The detection of SCs is based on the lack of pan T-cell markers such as CD7 and/or CD26, which is not constant and may be observed in benign dermatoses. Thus, patients are often diagnosed with a delay, even treated with inappropriate therapies which worsens their prognosis. The relevance of blood-class in MF/SS is not only related to stage but also contributes to the response to therapy in clinical trials. We found that a significant proportion of benign T-cells from SS patients are CD4+CD26-, which may underestimate the rate of complete response to treatment. The identification of KIR3DL2 on SCs by our team has greatly helped the detailed study of the malignant clone. We have recently published two ancillary studies demonstrating the specificity and reliability of KIR3DL2 as a positive marker for SCs, and its prognosis value at initial diagnosis. We have designed an optimized flow-cytometry strategy as part of the routine care of erythrodermic patients at Saint-Louis Hospital and published in 2019 the results of a 5 years prospective single-center study involving 254 CTCL patients at initial diagnosis. We provided recommendations with the use a threshold value of KIR3DL2+SCs ≥ 200/µL or KIR3DL2+SCs/lymphocytes ≥ 10% in the diagnostic criteria and proposed a novel algorithm blood staging.
Several innovative immunotherapies in phase I/II trials or under compassionate use are ongoing in French centers, with the need to assess blood response using positive markers. Our goal is to validate KIR3DL2 as a specific marker for SS and to assess its reliability for blood staging and response to treatment in a multicenter study (11 centers).
447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.
This study's planned enrollment of 460 is above the median of 100 across 51 observational studies indexed under Mycosis Fungoides.
Browse Mycosis Fungoides studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,596 studies on the registry; 1,037 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria for all patient :
Inclusion criteria for group 1 :
Inclusion criteria for group 2 :
Confirmed SS (previously diagnosed), followed at Saint Louis hospital participating center with all the following criteria:
B2 blood staging at initial diagnosis
Exclusion Criteria:
at initial diagnosis assessment
Other: Follow-up
Clinical evaluation Blood sample Skin biopsy
Specificity of KIR3DL2 in the diagnosis of Sezary syndrome
Defined as the proportion of patients KIR3DL2 \<200/mm3 among patients without SS. Diagnosis of SS is defined as the presence of each of the following criteria: * T4 tumoral stage (erythrodermia ≥ 80% of total body area) * the presence of an identical T-cell clone evidenced in blood and skin * B2 blood stage Of note, according to ISCL/EORTC recommendations, FCM (Flow cytometry) blood staging is defined as: Stage B2: Expanded CD4+T cells with either CD4+CD26-≥30%, or CD4+CD7-≥40% And/or either CD4+CD7- or CD4+CD26-Tcells≥1000/mm3 Stage B1: Either CD4+CD7- or CD4+CD26-T-cells ≥250/mm3, but not meeting B2 criteria Stage B0: CD4+CD7- and CD4+CD26-T-cells\<250/mm3 Diagnosis and KIR3DL2 measurements will be performed using standardized/harmonized procedures across participating laboratories, using the same combination of labelled antibodies, gating strategies and instrument settings.
Time frame: At baseline, for group 1
Receiver Operating Characteristics (ROC) curve (Sensitivity, Specificity, area under the ROC curve) of KIR3DL2 in the diagnosis of SS and mycosis fungoides (MF) in eligible patients.
The reference diagnosis of SS will be defined as in the primary endpoint. KIR3DL2 will be measured with by FCM. Sensitivity, Specificity and ROC curve will be estimated both with the absolute count of KIR3DL2 and with the percentage of KIR3DL2 within lymphocyte subset.
Time frame: At baseline, for group 1
Positive and Negative predictive values of KIR3DL2 for SS diagnosis in the population of patients with clinical features consistent with erythrodermic CTCL
Cut-off value used for KIR3DL2 : 200/mm3
Time frame: Up to 24 months for group 1 patients
Blood response
Blood response using FCM and CD7 and CD26 markers as per latest ISCL and EORTC guidelines, with the definition of: Complete response (CR) : B0 stage. Partial response (PR) : \> 50% decrease in quantitative measurements of blood tumor burden from baseline in those with B2 stage at baseline. Progressive disease (PD) : B0 to B2 or \>50% increase from baseline and at least 5000 neoplastic cells/ mm3 or Loss of response: in those with PR who were originally B2 at baseline, \> 50% increase from nadir. Stable disease (SD) : Fails to attain criteria for CR, PR, or PD. Relapse : increase of neoplastic blood lymphocytes to ≥ B2 in those with CR.
Time frame: At 3 months for group 1 and 2
Blood response
Blood response using FCM and CD7 and CD26 markers as per latest ISCL and EORTC guidelines, with the definition of: Complete response (CR) : B0 stage. Partial response (PR) : \> 50% decrease in quantitative measurements of blood tumor burden from baseline in those with B2 stage at baseline. Progressive disease (PD) : B0 to B2 or \>50% increase from baseline and at least 5000 neoplastic cells/ mm3 or Loss of response: in those with PR who were originally B2 at baseline, \> 50% increase from nadir. Stable disease (SD) : Fails to attain criteria for CR, PR, or PD. Relapse : increase of neoplastic blood lymphocytes to ≥ B2 in those with CR.
Time frame: At 6 months for group 1 and 2
Blood response
Blood response using FCM and CD7 and CD26 markers as per latest ISCL and EORTC guidelines, with the definition of: Complete response (CR) : B0 stage. Partial response (PR) : \> 50% decrease in quantitative measurements of blood tumor burden from baseline in those with B2 stage at baseline. Progressive disease (PD) : B0 to B2 or \>50% increase from baseline and at least 5000 neoplastic cells/ mm3 or Loss of response: in those with PR who were originally B2 at baseline, \> 50% increase from nadir. Stable disease (SD) : Fails to attain criteria for CR, PR, or PD. Relapse : increase of neoplastic blood lymphocytes to ≥ B2 in those with CR.
Time frame: At 9 months for group 1 and 2
Blood response
Blood response using FCM and CD7 and CD26 markers as per latest ISCL and EORTC guidelines, with the definition of: Complete response (CR) : B0 stage. Partial response (PR) : \> 50% decrease in quantitative measurements of blood tumor burden from baseline in those with B2 stage at baseline. Progressive disease (PD) : B0 to B2 or \>50% increase from baseline and at least 5000 neoplastic cells/ mm3 or Loss of response: in those with PR who were originally B2 at baseline, \> 50% increase from nadir. Stable disease (SD) : Fails to attain criteria for CR, PR, or PD. Relapse : increase of neoplastic blood lymphocytes to ≥ B2 in those with CR.
Time frame: At 12 months for group 1 and 2
Blood response
Blood response using FCM and CD7 and CD26 markers as per latest ISCL and EORTC guidelines, with the definition of: Complete response (CR) : B0 stage. Partial response (PR) : \> 50% decrease in quantitative measurements of blood tumor burden from baseline in those with B2 stage at baseline. Progressive disease (PD) : B0 to B2 or \>50% increase from baseline and at least 5000 neoplastic cells/ mm3 or Loss of response: in those with PR who were originally B2 at baseline, \> 50% increase from nadir. Stable disease (SD) : Fails to attain criteria for CR, PR, or PD. Relapse : increase of neoplastic blood lymphocytes to ≥ B2 in those with CR.
Time frame: At 15 months for group 1 and 2
Blood response
Blood response using FCM and CD7 and CD26 markers as per latest ISCL and EORTC guidelines, with the definition of: Complete response (CR) : B0 stage. Partial response (PR) : \> 50% decrease in quantitative measurements of blood tumor burden from baseline in those with B2 stage at baseline. Progressive disease (PD) : B0 to B2 or \>50% increase from baseline and at least 5000 neoplastic cells/ mm3 or Loss of response: in those with PR who were originally B2 at baseline, \> 50% increase from nadir. Stable disease (SD) : Fails to attain criteria for CR, PR, or PD. Relapse : increase of neoplastic blood lymphocytes to ≥ B2 in those with CR.
Time frame: At 18 months for group 1 and 2
Blood response
Blood response using FCM and CD7 and CD26 markers as per latest ISCL and EORTC guidelines, with the definition of: Complete response (CR) : B0 stage. Partial response (PR) : \> 50% decrease in quantitative measurements of blood tumor burden from baseline in those with B2 stage at baseline. Progressive disease (PD) : B0 to B2 or \>50% increase from baseline and at least 5000 neoplastic cells/ mm3 or Loss of response: in those with PR who were originally B2 at baseline, \> 50% increase from nadir. Stable disease (SD) : Fails to attain criteria for CR, PR, or PD. Relapse : increase of neoplastic blood lymphocytes to ≥ B2 in those with CR.
Time frame: At 21 months for group 1 and 2
Blood response
Blood response using FCM and CD7 and CD26 markers as per latest ISCL and EORTC guidelines, with the definition of: Complete response (CR) : B0 stage. Partial response (PR) : \> 50% decrease in quantitative measurements of blood tumor burden from baseline in those with B2 stage at baseline. Progressive disease (PD) : B0 to B2 or \>50% increase from baseline and at least 5000 neoplastic cells/ mm3 or Loss of response: in those with PR who were originally B2 at baseline, \> 50% increase from nadir. Stable disease (SD) : Fails to attain criteria for CR, PR, or PD. Relapse : increase of neoplastic blood lymphocytes to ≥ B2 in those with CR.
Time frame: At 24 months for group 1 and 2
Overall survival
Time frame: Up to 24 months for group 1
Progression free survival
Time frame: Up to 24 months for group 1
Minimal Residual Disease
Minimal Residual Disease (MRD) by multiparameter flow cytometric immunophenotyping and High Throughput Sequencing (HTS) based detection of clonal TCR gene rearrangements in patients with SS, at the time of CR remission, in comparison with baseline measurements on frozen PBMC.
Time frame: At 24 months for group 1 and 2
Evolution to SS diagnosis as defined in the primary endpoint in stage B1 patients with KIR3DL2≥ 200/mm3 or ≥ 10% at baseline
Time frame: Up to 24 months for group 1
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2024; primary completion for Nov 2027, 36 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →